Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tuberculosis drugs’ distribution and emergence of resistance in patient’s lung lesions: A mechanistic model and tool for regimen and dose optimization
Authors
Keywords
Lesions, Tuberculosis, Drug therapy, Drug research and development, Drug absorption, Mycobacterium tuberculosis, Surgical and invasive medical procedures, Drug distribution
Journal
PLOS MEDICINE
Volume 16, Issue 4, Pages e1002773
Publisher
Public Library of Science (PLoS)
Online
2019-04-03
DOI
10.1371/journal.pmed.1002773
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data
- (2018) Dalin Rifat et al. Science Translational Medicine
- Bacterial Factors That Predict Relapse after Tuberculosis Therapy
- (2018) Roberto Colangeli et al. NEW ENGLAND JOURNAL OF MEDICINE
- A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
- (2018) Marjorie Z. Imperial et al. NATURE MEDICINE
- High-resolution mapping of fluoroquinolones in TB rabbit lesions reveals specific distribution in immune cell types
- (2018) Landry Blanc et al. eLife
- The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?
- (2017) A. Reuter et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study
- (2017) M Tobias Heinrichs et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice
- (2016) Scott M. Irwin et al. ACS Infectious Diseases
- Prediction of Drug Penetration in Tuberculosis Lesions
- (2016) Jansy P. Sarathy et al. ACS Infectious Diseases
- Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum
- (2015) Jean-Philippe Lanoix et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In silico evaluation and exploration of antibiotic tuberculosis treatment regimens
- (2015) Elsje Pienaar et al. BMC Systems Biology
- The association between sterilizing activity and drug distribution into tuberculosis lesions
- (2015) Brendan Prideaux et al. NATURE MEDICINE
- Limited Activity of Clofazimine as a Single Drug in a Mouse Model of Tuberculosis Exhibiting Caseous Necrotic Granulomas
- (2014) Scott M. Irwin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid
- (2014) Lauren M. Boak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents
- (2014) Suresh B. Lakshminarayana et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
- (2014) Véronique Dartois NATURE REVIEWS MICROBIOLOGY
- A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis
- (2014) Corinne S. Merle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
- (2014) Stephen H. Gillespie et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
- (2014) Amina Jindani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions
- (2011) Maria C. Kjellsson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Additional Drug Resistance in Mycobacterium tuberculosis Isolates From Resected Cavities Among Patients With Multidrug-Resistant or Extensively Drug-Resistant Pulmonary Tuberculosis
- (2011) R. R. Kempker et al. CLINICAL INFECTIOUS DISEASES
- New Susceptibility Breakpoints for First-Line Antituberculosis Drugs Based on Antimicrobial Pharmacokinetic/Pharmacodynamic Science and Population Pharmacokinetic Variability
- (2010) T. Gumbo ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model
- (2010) G. L. Drusano et al. mBio
- The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
- (2009) Clifton E. Barry et al. NATURE REVIEWS MICROBIOLOGY
- Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations
- (2008) K. Dooley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now